null

SMILES: COCCOCCOCCNC(=O)c1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(nn4C)C(C)(C)C)c4ccccc34)ccn2)cc(c1)C#C

InChI Key: InChIKey=IIOPMAYJMMUZLO-UHFFFAOYSA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 342109   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Mitogen-activated protein kinase 12 (Homo sapiens (Human))	BDBM342109 (3-((4-((4-(3-(3-(tert-Butyl)-1-methyl-1H-pyrazol-5...) Show SMILES COCCOCCOCCNC(=O)c1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(nn4C)C(C)(C)C)c4ccccc34)ccn2)cc(c1)C#C Show InChI InChI=1S/C40H45N7O6/c1-7-27-22-28(38(48)42-16-17-51-20-21-52-19-18-50-6)24-29(23-27)43-36-25-30(14-15-41-36)53-34-13-12-33(31-10-8-9-11-32(31)34)44-39(49)45-37-26-35(40(2,3)4)46-47(37)5/h1,8-15,22-26H,16-21H2,2-6H3,(H,41,43)(H,42,48)(H2,44,45,49)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	66	n/a	n/a	n/a	n/a	n/a	n/a
TOPIVERT PHARMA LIMITED; RESPIVERT LIMITED US Patent					Assay Description p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...				US Patent US9771353 (2017) BindingDB Entry DOI: 10.7270/Q2HQ4219
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 alpha (Homo sapiens (Human))	BDBM342109 (3-((4-((4-(3-(3-(tert-Butyl)-1-methyl-1H-pyrazol-5...) Show SMILES COCCOCCOCCNC(=O)c1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(nn4C)C(C)(C)C)c4ccccc34)ccn2)cc(c1)C#C Show InChI InChI=1S/C40H45N7O6/c1-7-27-22-28(38(48)42-16-17-51-20-21-52-19-18-50-6)24-29(23-27)43-36-25-30(14-15-41-36)53-34-13-12-33(31-10-8-9-11-32(31)34)44-39(49)45-37-26-35(40(2,3)4)46-47(37)5/h1,8-15,22-26H,16-21H2,2-6H3,(H,41,43)(H,42,48)(H2,44,45,49)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.24E+4	n/a	n/a	n/a	n/a	n/a	n/a
TOPIVERT PHARMA LIMITED; RESPIVERT LIMITED US Patent					Assay Description The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...				US Patent US9771353 (2017) BindingDB Entry DOI: 10.7270/Q2HQ4219
					More data for this Ligand-Target Pair
Tyrosine-protein kinase SYK (Homo sapiens (Human))	BDBM342109 (3-((4-((4-(3-(3-(tert-Butyl)-1-methyl-1H-pyrazol-5...) Show SMILES COCCOCCOCCNC(=O)c1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(nn4C)C(C)(C)C)c4ccccc34)ccn2)cc(c1)C#C Show InChI InChI=1S/C40H45N7O6/c1-7-27-22-28(38(48)42-16-17-51-20-21-52-19-18-50-6)24-29(23-27)43-36-25-30(14-15-41-36)53-34-13-12-33(31-10-8-9-11-32(31)34)44-39(49)45-37-26-35(40(2,3)4)46-47(37)5/h1,8-15,22-26H,16-21H2,2-6H3,(H,41,43)(H,42,48)(H2,44,45,49)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>1.00E+3	n/a	n/a	n/a	n/a	n/a	n/a
TOPIVERT PHARMA LIMITED; RESPIVERT LIMITED US Patent					Assay Description GSK 3α: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determinin...				US Patent US9771353 (2017) BindingDB Entry DOI: 10.7270/Q2HQ4219
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human))	BDBM342109 (3-((4-((4-(3-(3-(tert-Butyl)-1-methyl-1H-pyrazol-5...) Show SMILES COCCOCCOCCNC(=O)c1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(nn4C)C(C)(C)C)c4ccccc34)ccn2)cc(c1)C#C Show InChI InChI=1S/C40H45N7O6/c1-7-27-22-28(38(48)42-16-17-51-20-21-52-19-18-50-6)24-29(23-27)43-36-25-30(14-15-41-36)53-34-13-12-33(31-10-8-9-11-32(31)34)44-39(49)45-37-26-35(40(2,3)4)46-47(37)5/h1,8-15,22-26H,16-21H2,2-6H3,(H,41,43)(H,42,48)(H2,44,45,49)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	53	n/a	n/a	n/a	n/a	n/a	n/a
TOPIVERT PHARMA LIMITED; RESPIVERT LIMITED US Patent					Assay Description c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...				US Patent US9771353 (2017) BindingDB Entry DOI: 10.7270/Q2HQ4219
					More data for this Ligand-Target Pair